The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. You can do a quick search to filter our featured studies by cancer type, study type or key word, or a more in-depth search through clinicaltrials.gov.
Search Results: Treatment + Colorectal Cancer + Stage 4 (7 results)
Treatment
Any advanced or metastatic solid tumor except ovarian or prostate
PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)
PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an
advanced solid tumor with either an inherited or tumor PALB2 mutation.
Treatment
Stage 4 colorectal cancer
Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer
The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus four other treatments in patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic (stage IV) Colorectal Cancer.
Treatment
Advanced solid tumors
A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors
This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage.
Treatment
Metastatic colorectal, pancreatic, gastroesophageal or biliary tract cancer
Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib
This study is focused on patients with pancreatic, colorectal, gastroesophageal, or biliary (bile duct) cancer that has spread to other places in the body (metastasized).
Chemotherapy drugs, such as liposomal irinotecan and fluorouracil damage cancer cells. Targeted therapies such as rucaparib, can keep cancer cells from being able to repair damage.
This study will look at how the targeted therapy rucaparib works with chemotherapy in treating patients with metastatic pancreatic, colorectal, gastroesophageal, or biliary cancer. The study will measure the best dose and look at sides effects with this combination of drugs.
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.
Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.
Treatment
Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study
This study is for people with metastatic colorectal cancer. The study will compare how well treatment with a combination of chemotherapy agents and an immunotherapy agent works compared with treatment using an immunotherapy agent alone. This study is focused on patients who are determined to be mismatch-repair deficient (dMMR) or have an MSI-H diagnosis, which are commonly seen in people with Lynch syndrome.
Treatment
People with metastatic colorectal cancer that is MSI-High
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)
The purpose of this study is to compare the benefit of the combination of immunotherapy agents Nivolumab plus Ipilimumab in patients who have Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer versus using Nivolumab as a single therapy or chemotherapy.
Additional Results on Clinicaltrials.gov Treatment + Colorectal Cancer + Stage 4
146 results
Research Search Tool Sponsored By:
